16:03 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Concert's hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) reported Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa products from Pfizer Inc. (NYSE:PFE). Twice-daily 8 mg...
00:38 , Nov 13, 2018 |  BC Extra  |  Clinical News

Concert stock falls as hair loss product meets in Phase IIa, but with slower onset than Pfizer's

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) lost $3.47 (22%) to $12.59 on Monday after reporting Phase IIa data suggesting that its JAK inhibitor CTP-543 may have a later onset in treating alopecia areata than competing Phase IIa...
17:59 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

FDA grants Priority Review to Incyte's Jakafi for acute GvHD

Incyte Corp. (NASDAQ:INCY) said FDA accepted and granted Priority Review to an sNDA seeking approval for Jakafi ruxolitinib to treat acute graft-versus-host disease (GvHD) in patients with inadequate response to corticosteroids. The PDUFA date was...
19:32 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Encephalopathy Patient sample and mouse studies suggest inhibiting the JAK/STAT1 pathway, the interaction between MCP-1 and CCR2, or phagocyte activation could help treat Rasmussen encephalitis. In postmortem brain samples from patients, levels of phosphorylated...
18:29 , Aug 31, 2018 |  BC Week In Review  |  Company News

Sierra Oncology acquires momelotinib from Gilead

Sierra Oncology Inc. (NASDAQ:SRRA) acquired momelotinib (formerly CYT387) from Gilead Sciences Inc. (NASDAQ:GILD) for $3 million up front and up to $195 million in milestones. Gilead is also eligible for tiered royalties ranging from mid-teens...
17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; cervical cancer; head and neck cancer; lung cancer; ovarian cancer Patient sample, cell culture and mouse studies suggest inhibiting MAST1 could help treat cisplatin-resistant cancer. In tumor samples from squamous cell carcinoma of...
16:05 , Aug 16, 2018 |  BC Innovations  |  Distillery Therapeutics

Gastrointestinal

INDICATION: Gastrointestinal Mouse studies suggest inhibiting JAK-1 and JAK-2, RAG2 or IL-6 could help treat Peutz-Jeghers syndrome, which involves the formation of benign gastrointestinal polyps. In a mouse model of the disease, systemic knockout of...
19:22 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Incyte's Jakafi meets in Phase II for steroid-refractory GvHD

Incyte Corp. (NASDAQ:INCY) said Jakafi ruxolitinib in combination with corticosteroids met the primary endpoint in the U.S. Phase II REACH1 trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company plans to submit an sNDA...
21:38 , Jul 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer; infectious disease

INDICATION: Acute myelogenous leukemia (AML); Candida In vitro , cell culture and mouse studies identified an aminopyrimidine-based dual JAK-2/HDAC6 inhibitor that could help treat AML and Candida albicans infection. Chemical synthesis of aminopyrimidine analogs linked...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...